RESUMO
Background: 5-fluorouracil (5-FU) was the standard treatment care for colorectal cancer (CRC), however, its efficacy was limited due to safety concerns. Capecitabine and oxaliplatin (CAPOX) treatment was found equivalent to 5-FU in efficacy and preferred now due to easy management and convenience in administration. Hence, the present study aims to determine the efficacy and safety associated with CAPOX treatment in a real world non clinical setting. Methods: 145 treatment-naive and newly diagnosed CRC patients were recruited in the study. Each patient received oxaliplatin 130 mg/m2 infusion over 2 hours on day 1 and oral capecitabine 1000 mg/m2 in divided doses twice daily for the next 14 days of a 21-day cycle. Results: In the adjuvant setting, the observed disease-free survival rate was 62% (n=34) in the colon and 67% (n=15) in the rectum cancer patients at 2 years. The observed overall survival rate in the colon and rectal cancer was 80% (n=44) and 83% (n=18) respectively at 2 years. In the palliative setting the observed progression-free survival rate was 28% (n=13) in the colon and 33% (n=7) in rectal cancer patients at 2 years. The observed OSR at 2 years was 64% (n=30) in the colon and 67% (n=14) in the rectal cancer patients. Thrombocytopenia (17, 11.7%) and diarrhea (8, 5.5%) were the most commonly observed grade 3/4 hematological and gastrointestinal toxicities. Hand-foot syndrome and peripheral neuropathy were the major contributors for dose reduction (14, 9.6%), treatment delay (8, 5.4%), and drug discontinuation (9, 6.1%) in the study cohort. Conclusion: CAPOX treatment was found to be effective but associated with several dose-limiting toxicities.
RESUMO
Objective:To study the effect of CAPOX regimen and SOX regimen in the treatment of advanced gastric cancer.Methods:140 patients with advanced gastric cancer who received chemotherapy from January 2010 to June 2011 in the hospital were enrolled in this study.The patients were divided into observation group (CAPOX regimen) 72 cases and control group(SOX regimen) 68 cases according to the different chemotherapy protocols,two groups were treated with central venous catheter,and in the course of chemotherapy for the given antiemetic,hepatoprotective and Acid suppression related drugs.The observation group was treated with CAPOX regimen,and the control group was treated with SOX regimen,and the 21d was used as the 1 chemotherapy cycle,and the effect was evaluated after 2 cycles of chemotherapy.Results:The effective rate of observation group was 33.33％ (24/72),compared with the control group of 33.82％(23/68),the difference was not statistically significant (P＞0.05).The incidence of hand foot syndrome in the observation group was 16.67％ (12/72),was significantly higher than the control group of 2.94％(2/68),the difference was statistically significant(P＜0.05).The total incidence of adverse reactions in the observation group was 58.33％ (42/72),compared with the control group of 57.35％(39/68),the difference was not statistically significant(P＞0.05).The 1 to 5 year survival rate of the observation group compared with the control group was not statistically significant(P＞0.05).The two groups before and after treatment of CD3+,CD3+CD4+ and CD3+/CD8+ compared,the difference was not statistically significant (P＞0.05).Conclusion:Using CAPOX scheme and the SOX regimen can be better in the treatment of advanced gastric cancer,curative effect and short and long term survival rate was almost equal and influence of immune function of patients with no significant difference,but CAPOX scheme may exist higher hand foot syndrome probability,it is worth clinical optic.